Pathology

When Bladder Cancer Histology Changes the Clinical Picture

Not all bladder cancers follow the same clinical course. Histologic subtypes such as micropapillary, plasmacytoid, sarcomatoid, and neuroendocrine carcinoma can behave differently from conventional urothelial carcinoma, often presenting at more advanced stages and carrying a greater risk of progression. A recent review highlights how recognizing these subtypes, and understanding the molecular alterations underlying them, may become increasingly important for risk assessment and treatment planning.

The distinction begins with pathology. Updated World Health Organization classifications differentiate histologic subtypes from divergent differentiation, including urothelial carcinoma with squamous or glandular differentiation. These tumors are considered high grade, but their biological behavior can vary considerably. Micropapillary carcinoma, for example, has a propensity for advanced and node-positive disease, while plasmacytoid carcinoma is characterized by a highly infiltrative growth pattern that can facilitate spread across tissue planes. Neuroendocrine and sarcomatoid tumors are also associated with aggressive clinical behavior.

Molecular profiling is beginning to reveal why these tumors may behave differently. Micropapillary carcinoma has been associated with alterations involving ERBB2, while loss of CDH1 and E-cadherin expression is a defining molecular feature of plasmacytoid carcinoma and may contribute to its discohesive, infiltrative behavior. Neuroendocrine bladder cancer frequently demonstrates alterations in TP53 and RB1, including co-alterations that may help drive its distinct biology. Sarcomatoid tumors also demonstrate a different molecular profile, including frequent TP53, PIK3CA, and RB1 alterations.

These biological differences may have therapeutic implications, but the evidence is far from uniform. Retrospective studies suggest that some subtypes can respond to systemic therapy, while others demonstrate variable sensitivity to conventional approaches. Even within an individual subtype, findings are not always consistent across studies. Histologic composition can also matter. For example, reporting the proportion of a neuroendocrine component is clinically relevant because even a small-cell component can influence treatment considerations. These differences reinforce the importance of accurate pathologic characterization rather than treating variant histology as a single clinical entity.

For urologists, the challenge is that increasingly detailed biological information is emerging faster than high-quality prospective evidence. Patients with these less common bladder cancer subtypes have historically been underrepresented in clinical trials, leaving many treatment decisions dependent on retrospective studies and extrapolation from conventional urothelial carcinoma. Greater inclusion of variant histologies in prospective trials, combined with molecular profiling and standardized pathologic reporting, could ultimately help determine which biological differences meaningfully affect prognosis and treatment selection.